MedTrace Logo

trūFreeze® Palliative Esophageal Cancer

NCT03243734 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2024-05-08

No results posted yet for this study

Summary

Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.

Conditions

  • Esophageal Cancer

Interventions

DEVICE

trūFreeze® System spray cryotherapy

Subjects where trūFreeze® System spray cryotherapy is performed

Sponsors & Collaborators

  • US Endoscopy Group Inc.

    lead INDUSTRY

Principal Investigators

  • Nicholas Shaheen, MD · University of North Carolina, Chapel Hill

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2022-07-13
Completion
2024-03-06
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03243734 on ClinicalTrials.gov